Skip Navigation


NDT Advance Access originally published online on August 8, 2007
Nephrology Dialysis Transplantation 2007 22(12):3674-3676; doi:10.1093/ndt/gfm514
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
22/12/3674    most recent
gfm514v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pansini, F.
Right arrow Articles by Schena, F. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pansini, F.
Right arrow Articles by Schena, F. P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org


Rituximab induces complete remission in a case of membranous nephropathy associated with hepatitis C virus- related infection

Email: c.manno@nephro.uniba.it

The first 10% of the full text of this article appears below.

Sir,

Idiopathic membranous nephropathy (MN) is the most common cause of nephrotic syndrome in adults. Corticosteroids, cytotoxic agents and cyclosporine have been largely used in idiopathic MN, but their use may be ineffective or contraindicated in some patients [1]. The pathogenetic potential of B cells in this disease has been employed to explore the therapeutic use of new drugs, such as rituximab, a monoclonal antibody to B-cell antigen CD20. CD20 expression is limited to B cells, begins in humans at the early pre-B-cell stage, and persists until the B cells undergo terminal plasma cell differentiation. The binding of rituximab to the surface receptor of B cells inhibits their activation, proliferation, differentiation and . . . [Full Text of this Article]

Case report

Comments

Francesca Pansini*, Carmen Bonifati*, Carlo Manno and Francesco Paolo Schena

Department of Emergency and
Organ Transplantation,
Renal, Dialysis and
Transplant Unit,
University of Bari,
Bari,
Italy


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 CJASNHome page
A. S. Bomback, V. K. Derebail, J. G. McGregor, A. V. Kshirsagar, R. J. Falk, and P. H. Nachman
Rituximab Therapy for Membranous Nephropathy: A Systematic Review
Clin. J. Am. Soc. Nephrol., April 1, 2009; 4(4): 734 - 744.
[Abstract] [Full Text] [PDF]